Guide for diagnosis and treatment of hepatocellular carcinoma

World Journal of Hepatology

Volumn 7, Issue 12, 2015, Pages 1632-1651

  Attwa, Magdy Hamed ^a   El Etreby, Shahira Aly ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Diagnosis of hepatocellular carcinoma; Hepatocellular carcinoma; Liver transplantation; Microwave ablation; Percutaneous ethanol or acetic acid ablation; Radio embolisation; Radiofrequency ablation; Surgical resection; Systemic chemotherapy; Transarterial chemoembolisation

Indexed keywords

EID: 84934277643     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i12.1632     Document Type: Review

References (175)

1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.e1 [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061].
2. Rahman El-Zayadi A, Abaza H, Shawky S, Mohamed MK, Selim OE, Badran HM. Prevalence and epidemiological features of hepatocellular carcinoma in Egypt-a single center experience. Hepatol Res 2001; 19: 170-179 [PMID: 11164741 DOI: 10.1016/S1386-6346(00)00105-4].
3. El-Zayadi AR, Badran HM, Barakat EM, Attia Mel-D, Shawky S, Mohamed MK, Selim O, Saeid A. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol 2005; 11: 5193-5198 [PMID: 16127751].
4. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87-107, vi [PMID: 11218921 DOI: 10.1016/S1089-3261(05)70155-0].
5. Arafa N, El Hoseiny M, Rekacewicz C, Bakr I, El-Kafrawy S, El Daly M, Aoun S, Marzouk D, Mohamed MK, Fontanet A. Changing pattern of hepatitis C virus spread in rural areas of Egypt. J Hepatol 2005; 43: 418-424 [PMID: 16019104 DOI: 10.1016/j.jhep.2005.03.021].
6. Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail NN, Esmat G, Fix A. Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg 2002; 67: 436-442 [PMID: 12452500].
7. Moradpour D, Blum HE. Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005; 17: 477-483 [PMID: 15827436 DOI: 10.1097/00042737-200505000-00002].
8. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for earlystage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47 [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x].
9. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199].
10. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001].
11. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255 [PMID: 22353262].
12. Stevens WR, Johnson CD, Stephens DH, Batts KP. CT findings in hepatocellular carcinoma: correlation of tumor characteristics with causative factors, tumor size, and histologic tumor grade. Radiology 1994; 191: 531-537 [PMID: 8153335 DOI: 10.1148/radiology.191.2.8153335].
13. Sugano S, Miyoshi K, Suzuki T, Kawafune T, Kubota M. Intrahepatic arteriovenous shunting due to hepatocellular carcinoma and cirrhosis, and its change by transcatheter arterial embolization. Am J Gastroenterol 1994; 89: 184-188 [PMID: 8304300].
14. Kew MC, Hodkinson J. Rupture of hepatocellular carcinoma as a result of blunt abdominal trauma. Am J Gastroenterol 1991; 86: 1083-1085 [PMID: 1650131].
15. Choi BG, Park SH, Byun JY, Jung SE, Choi KH, Han JY. The findings of ruptured hepatocellular carcinoma on helical CT. Br J Radiol 2001; 74: 142-146 [PMID: 11718385 DOI: 10.1259/bjr.74.878.740142].
16. Chearanai O, Plengvanit U, Asavanich C, Damrongsak D, Sindhvananda K, Boonyapisit S. Spontaneous rupture of primary hepatoma: report of 63 cases with particular reference to the pathogenesis and rationale treatment by hepatic artery ligation. Cancer 1983; 51: 1532-1536 [PMID: 6297703].
17. Kew MC, Dos Santos HA, Sherlock S. Diagnosis of primary cancer of the liver. Br Med J 1971; 4: 408-411 [PMID: 5124443 DOI: 10.1136/bmj.4.5784.408].
18. Bruix J, Castells A, Calvet X, Feu F, Bru C, Solé M, Bruguera M, Rodés J. Diarrhea as a presenting symptom of hepatocellular carcinoma. Dig Dis Sci 1990; 35: 681-685 [PMID: 2160881 DOI: 10.1007/BF01540166].
19. Lin YT, Liu CJ, Chen TJ, Chen TL, Yeh YC, Wu HS, Tseng CP, Wang FD, Tzeng CH, Fung CP. Pyogenic liver abscess as the initial manifestation of underlying hepatocellular carcinoma. Am J Med 2011; 124: 1158-1164 [PMID: 22114829 DOI: 10.1016/j.amjmed.2011.08.012].
20. Luo JC, Hwang SJ, Wu JC, Lai CR, Li CP, Chang FY, Chiang JH, Lui WY, Chu CW, Lee SD. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology 2002; 49: 1315-1319 [PMID: 12239934].
21. Eastman RC, Carson RE, Orloff DG, Cochran CS, Perdue JF, Rechler MM, Lanau F, Roberts CT, Shapiro J, Roth J. Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography. J Clin Invest 1992; 89: 1958-1963 [PMID: 1318326 DOI: 10.1172/JCI115803].
22. Yeung RT. Hypoglycaemia in hepatocellular carcinoma: a review. Hong Kong Med J 1997; 3: 297-301 [PMID: 11847375].
23. Tietge UJ, Schöfl C, Ocran KW, Wagner S, Böker KH, Brabant G, Zapf J, Manns MP. Hepatoma with severe non-islet cell tumor hypoglycemia. Am J Gastroenterol 1998; 93: 997-1000 [PMID: 9647037 DOI: 10.1111/j.1572-0241.1998.00297.x].
24. Thipaporn T, Bubpha P, Varaphon V. Hepatocellular carcinoma with persistent hypoglycemia: successful treatment with corticosteroid and frequent high carbohydrate intake. J Med Assoc Thai 2005; 88: 1941-1946 [PMID: 16518997].
25. Nikeghbalian S, Bananzadeh A, Yarmohammadi H. Hypoglycemia, the first presenting sign of hepatocellular carcinoma. Saudi Med J 2006; 27: 387-388 [PMID: 16532104].
26. Jayaprasad N, Anees T, Bijin T, Madhusoodanan S. Severe hypoglycemia due to poorly differentiated hepatocellular carcinoma. J Assoc Physicians India 2006; 54: 413-415 [PMID: 16909744].
27. Sorlini M, Benini F, Cravarezza P, Romanelli G. Hypoglycemia, an atypical early sign of hepatocellular carcinoma. J Gastrointest Cancer 2010; 41: 209-211 [PMID: 20204540 DOI: 10.1007/s12029-010-9137-0].
28. Kew MC, Fisher JW. Serum erythropoietin concentrations in patients with hepatocellular carcinoma. Cancer 1986; 58: 2485-2488 [PMID: 2429757].
29. Sakisaka S, Watanabe M, Tateishi H, Harada M, Shakado S, Mimura Y, Gondo K, Yoshitake M, Noguchi K, Hino T. Erythropoietin production in hepatocellular carcinoma cells associated with polycythemia: immunohistochemical evidence. Hepatology 1993; 18: 1357-1362 [PMID: 7694895 DOI: 10.1002/hep.1840180612].
30. Hwang SJ, Luo JC, Li CP, Chu CW, Wu JC, Lai CR, Chiang JH, Chau GY, Lui WY, Lee CC, Chang FY, Lee SD. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10: 2472-2477 [PMID: 15300887].
31. Carr BI, Guerra V. Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci 2013; 58: 1790-1796 [PMID: 23314854 DOI: 10.1007/s10620-012-2527-3].
32. Knill-Jones RP, Buckle RM, Parsons V, Calne RY, Williams R. Hypercalcemia and increased parathyroid-hormone activity in a primary hepatoma. Studies before and after hepatic transplantation. N Engl J Med 1970; 282: 704-708 [PMID: 4313545 DOI: 10.1056/NEJM197003262821302].
33. Yen TC, Hwang SJ, Wang CC, Lee SD, Yeh SH. Hypercalcemia and parathyroid hormone-related protein in hepatocellular carcinoma. Liver 1993; 13: 311-315 [PMID: 8295494 DOI: 10.1111/j.1600-0676.1993.tb00651.x].
34. Steiner E, Velt P, Gutierrez O, Schwartz S, Chey W. Hepatocellular carcinoma presenting with intractable diarrhea. A radiologicpathologic correlation. Arch Surg 1986; 121: 849-851 [PMID: 3013124 DOI: 10.1001/archsurg.1986.01400070119025].
35. Helzberg JH, McPhee MS, Zarling EJ, Lukert BP. Hepatocellular carcinoma: an unusual course with hyperthyroidism and inappropriate thyroid-stimulating hormone production. Gastroenterology 1985; 88: 181-184 [PMID: 2981080 DOI: 10.1016/S0016-5085(85)80152-9].
36. Summerskill WH, Adson MA. Gynecomastia as a sign of hepatoma. Report of a case. Am J Dig Dis 1962; 7: 250-254 [PMID: 13918386 DOI: 10.1007/BF02231817].
37. Kew MC, Leckie BJ, Greeff MC. Arterial hypertension as a paraneoplastic phenomenon in hepatocellular carcinoma. Arch Intern Med 1989; 149: 2111-2113 [PMID: 2549897 DOI: 10.1001/archinte.149.9.2111].
38. Kao WY, Hung HH, Lu HC, Lin HC, Wu JC, Lee SD, Su CW. Hepatocellular carcinoma with presentation of budd-Chiari syndrome. J Chin Med Assoc 2010; 73: 93-96 [PMID: 20171589 DOI: 10.1016/S1726-4901(10)70008-3].
39. Bargalló X, Gilabert R, Nicolau C, García-Pagán JC, Ayuso JR, Brú C. Sonography of Budd-Chiari syndrome. AJR Am J Roentgenol 2006; 187: W33-W41 [PMID: 16794137 DOI: 10.2214/AJR.04.0918].
40. Balaceanu LA, Diaconu CC, Aron G. Budd-Chiari syndrome as an initial presentation of hepatocellular carcinoma: a case report. Med Ultrason 2014; 16: 172-174 [PMID: 24791850 DOI: 10.11152/mu.2013.2066.162.lab1].
41. Gregory B, Ho VC. Cutaneous manifestations of gastrointestinal disorders. Part II. J Am Acad Dermatol 1992; 26: 371-383 [PMID: 1307219 DOI: 10.1016/0190-9622(92)70019-C].
42. Berkowitz I, Hodkinson HJ, Kew MC, Di Bisceglie AM. Pityriasis rotunda as a cutaneous marker of hepatocellular carcinoma: a comparison with its prevalence in other diseases. Br J Dermatol 1989; 120: 545-549 [PMID: 2543437 DOI: 10.1111/j.1365-2133.1989. tb01329.x].
43. Lim HW, Mascaro JM. The porphyrias and hepatocellular carcinoma. Dermatol Clin 1995; 13: 135-142 [PMID: 7712639].
44. Kew MC. Tumors of the liver. Hepatology: A textbook of liver disease. Philadelphia: WB Saunders Company, 1996: 1513.
45. Lai CL, Ng RP, Lok AS. The diagnostic value of the ratio of serum gamma-glutamyl transpeptidase to alkaline phosphatase in alcoholic liver disease. Scand J Gastroenterol 1982; 17: 41-47 [PMID: 6127789 DOI: 10.3109/00365528209181042].
46. Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15: 1301-1314 [PMID: 19294759 DOI: 10.3748/wjg. 15.1301].
47. Bhosale P, Szklaruk J, Silverman PM. Current staging of hepatocellular carcinoma: imaging implications. Cancer Imaging 2006; 6: 83-94 [PMID: 16829469 DOI: 10.1102/1470-7330.2006.0 014].
48. Fasani P, Sangiovanni A, De Fazio C, Borzio M, Bruno S, Ronchi G, Del Ninno E, Colombo M. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis attributable to multiple risk factors. Hepatology 1999; 29: 1704-1707 [PMID: 10347111 DOI: 10.1002/hep.510290604].
49. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432-438 [PMID: 7543434 DOI: 10.1002/hep.1840220210].
50. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, Coderc E, Reboullet P, Beaugrand M. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65-71 [PMID: 7515408 DOI: 10.1016/S0168-8278(05)80468-4].
51. Larcos G, Sorokopud H, Berry G, Farrell GC. Sonographic screening for hepatocellular carcinoma in patients with chronic hepatitis or cirrhosis: an evaluation. AJR Am J Roentgenol 1998; 171: 433-435 [PMID: 9694470 DOI: 10.2214/ajr.171.2.9694470].
52. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101: 513-523 [PMID: 16542288 DOI: 10.1111/j.1572-0241.2006.00467. x].
53. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933].
54. Dodd GD, Miller WJ, Baron RL, Skolnick ML, Campbell WL. Detection of malignant tumors in end-stage cirrhotic livers: efficacy of sonography as a screening technique. AJR Am J Roentgenol 1992; 159: 727-733 [PMID: 1326883 DOI: 10.2214/ajr.159.4.1326883].
55. França AV, Elias Junior J, Lima BL, Martinelli AL, Carrilho FJ. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res 2004; 37: 1689-1705 [PMID: 15517086 DOI: 10.1590/S0100-879X2004001100015].
56. Yu SC, Yeung DT, So NM. Imaging features of hepatocellular carcinoma. Clin Radiol 2004; 59: 145-156 [PMID: 14746783 DOI: 10.1016/S0009-9260(03)00316-7].
57. Albrecht T, Blomley M, Bolondi L, Claudon M, Correas JM, Cosgrove D, Greiner L, Jäger K, Jong ND, Leen E, Lencioni R, Lindsell D, Martegani A, Solbiati L, Thorelius L, Tranquart F, Weskott HP, Whittingham T. Guidelines for the use of contrast agents in ultrasound. January 2004. Ultraschall Med 2004; 25: 249-256 [PMID: 15300497 DOI: 10.1055/s-2004-813245].
58. Quaia E. Microbubble ultrasound contrast agents: an update. Eur Radiol 2007; 17: 1995-2008 [PMID: 17351779 DOI: 10.1007/s00330-007-0623-0].
59. Pompili M, Riccardi L, Semeraro S, Orefice R, Elia F, Barbaro B, Covino M, Grieco A, Gasbarrini G, Rapaccini GL. Contrastenhanced ultrasound assessment of arterial vascularization of small nodules arising in the cirrhotic liver. Dig Liver Dis 2008; 40: 206-215 [PMID: 18054850 DOI: 10.1016/j.dld.2007.10.006].
60. Westwood M, Joore M, Grutters J, Redekop K, Armstrong N, Lee K, Gloy V, Raatz H, Misso K, Severens J, Kleijnen J. Contrastenhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess 2013; 17: 1-243 [PMID: 23611316 DOI: 10.3310/hta17160].
61. Singh P, Erickson RA, Mukhopadhyay P, Gopal S, Kiss A, Khan A, Ulf Westblom T. EUS for detection of the hepatocellular carcinoma: results of a prospective study. Gastrointest Endosc 2007; 66: 265-273 [PMID: 17543307 DOI: 10.1016/j.gie.2006.10.053].
62. Crowe DR, Eloubeidi MA, Chhieng DC, Jhala NC, Jhala D, Eltoum IA. Fine-needle aspiration biopsy of hepatic lesions: computerized tomographic-guided versus endoscopic ultrasoundguided FNA. Cancer 2006; 108: 180-185 [PMID: 16634071 DOI: 10.1002/cncr.21912].
63. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430 [PMID: 11592607 DOI: 10.1016/S0168-8278(01)00130-1].
64. Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 2004; 127: S133-S143 [PMID: 15508077 DOI: 10.1053/j.gastro.2004.09.027].
65. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford) 2005; 7: 26-34 [PMID: 18333158 DOI: 10.1080/13651820410024049].
66. Onishi H, Murakami T, Nakamura H. Diagnosis of hepatocellular carcinoma: multidetector-row computed tomography and magnetic resonance imaging. In: Hayat MA, editor. Methods of cancer diagnosis, therapy and prognosis, Volume 5. Netherlands: Springer, 2009: 221-235 [DOI: 10.1007/978-1-4020-9804-8_16].
67. Saar B, Kellner-Weldon F. Radiological diagnosis of hepatocellular carcinoma. Liver Int 2008; 28: 189-199 [PMID: 18251978 DOI: 10.1111/j.1478-3231.2007.01655.x].
68. Szklaruk J, Silverman PM, Charnsangavej C. Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma. AJR Am J Roentgenol 2003; 180: 441-454 [PMID: 12540450 DOI: 10.2214/ajr.180.2.1800441].
69. Yu NC, Chaudhari V, Raman SS, Lassman C, Tong MJ, Busuttil RW, Lu DS. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011; 9: 161-167 [PMID: 20920597 DOI: 10.1016/j.cgh.2010.09.017].
70. Ishiguchi T, Shimamoto K, Fukatsu H, Yamakawa K, Ishigaki T. Radiologic diagnosis of hepatocellular carcinoma. Semin Surg Oncol 1996; 12: 164-169 [PMID: 8727605].
71. Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D, Pirenne J, Nevens F, Desmet V, Roskams T. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002; 8: 749-761 [PMID: 12200773 DOI: 10.1053/jlts.2002.34922].
72. Kunishi Y, Numata K, Morimoto M, Okada M, Kaneko T, Maeda S, Tanaka K. Efficacy of fusion imaging combining sonography and hepatobiliary phase MRI with Gd-EOB-DTPA to detect small hepatocellular carcinoma. AJR Am J Roentgenol 2012; 198: 106-114 [PMID: 22194485 DOI: 10.2214/AJR.10.6039].
73. Park MJ, Kim YK, Lee MW, Lee WJ, Kim YS, Kim SH, Choi D, Rhim H. Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 2012; 264: 761-770 [PMID: 22843769 DOI: 10.1148/radiol.12112517].
74. Granito A, Galassi M, Piscaglia F, Romanini L, Lucidi V, Renzulli M, Borghi A, Grazioli L, Golfieri R, Bolondi L. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the noninvasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2013; 37: 355-363 [PMID: 23199022 DOI: 10.1111/apt.12166].
75. Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, Caralt T, Ayuso JR, Solé M, Sanchez M, Brú C, Bruix J. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38: 1034-1042 [PMID: 14512891 DOI: 10.1002/hep.1840380430].
76. Lencioni R, Mascalchi M, Caramella D, Bartolozzi C. Small hepatocellular carcinoma: differentiation from adenomatous hyperplasia with color Doppler US and dynamic Gd-DTPAenhanced MR imaging. Abdom Imaging 1996; 21: 41-48 [PMID: 8672971 DOI: 10.1007/s002619900007].
77. Nanda NC, Schlief R. Advances in echo imaging using contrast enhancement. Dordrecht: Kluwer Academic Publishers, 1993.
78. Heiken JP, Weyman PJ, Lee JK, Balfe DM, Picus D, Brunt EM, Flye MW. Detection of focal hepatic masses: prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging. Radiology 1989; 171: 47-51 [PMID: 2538862 DOI: 10.1148/radiology.171.1.2538862].
79. Yu JS, Kim KW, Lee JT, Yoo HS. MR imaging during arterial portography for assessment of hepatocellular carcinoma: comparison with CT during arterial portography. AJR Am J Roentgenol 1998; 170: 1501-1506 [PMID: 9609162 DOI: 10.2214/ajr.170.6.9609162].
80. Kanematsu M, Hoshi H, Murakami T, Inaba Y, Kim T, Yamada T, Kato M, Yokoyama R, Nakamura H. Detection of hepatocellular carcinoma in patients with cirrhosis: MR imaging versus angiographically assisted helical CT. AJR Am J Roentgenol 1997; 169: 1507-1515 [PMID: 9393154 DOI: 10.2214/ajr.169.6.9393154].
81. Murakami T, Oi H, Hori M, Kim T, Takahashi S, Tomoda K, Narumi Y, Nakamura H. Helical CT during arterial portography and hepatic arteriography for detecting hypervascular hepatocellular carcinoma. AJR Am J Roentgenol 1997; 169: 131-135 [PMID: 9207512 DOI: 10.2214/ajr.169.1.9207512].
82. Kanematsu M, Hoshi H, Imaeda T, Murakami T, Inaba Y, Yokoyama R, Nakamura H. Detection and characterization of hepatic tumors: value of combined helical CT hepatic arteriography and CT during arterial portography. AJR Am J Roentgenol 1997; 168: 1193-1198 [PMID: 9129410 DOI: 10.2214/ajr.168.5.9129410].
83. Ikeda K, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama K, Kumada H. Imaging diagnosis of small hepatocellular carcinoma. Hepatology 1994; 20: 82-87 [PMID: 8020908 DOI: 10.1002/hep.1840200113].
84. Ohki T, Tateishi R, Akahane M, Mikami S, Sato M, Uchino K, Arano T, Enooku K, Kondo Y, Yamashiki N, Goto T, Shiina S, Yoshida H, Matsuyama Y, Omata M, Ohtomo K, Koike K. CT with hepatic arterioportography as a pretreatment examination for hepatocellular carcinoma patients: a randomized controlled trial. Am J Gastroenterol 2013; 108: 1305-1313 [PMID: 23629602 DOI: 10.1038/ajg.2013.109].
85. El-Bahrawy M. Alpha-fetoprotein-producing non-germ cell tumours of the female genital tract. Eur J Cancer 2010; 46: 1317-1322 [PMID: 20185298 DOI: 10.1016/j.ejca.2010.01.028].
86. Liu X, Cheng Y, Sheng W, Lu H, Xu Y, Long Z, Zhu H, Wang Y. Clinicopathologic features and prognostic factors in alphafetoprotein-producing gastric cancers: analysis of 104 cases. J Surg Oncol 2010; 102: 249-255 [PMID: 20740583 DOI: 10.1002/jso.21624].
87. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273-278 [PMID: 9425947 DOI: 10.1002/hep.510270140].
88. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012; 107: 64-74 [PMID: 21931376 DOI: 10.1038/ajg.2011.312].
89. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, Lee WM, Morgan TR, Ghany MG, Gretch DR. Serum alphafetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005; 43: 434-441 [PMID: 16136646 DOI: 10.1016/j.jhep.2005.03.019].
90. Chen DS, Sung JL, Sheu JC, Lai MY, How SW, Hsu HC, Lee CS, Wei TC. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984; 86: 1404-1409 [PMID: 6201411].
91. Soreide O, Czerniak A, Bradpiece H, Bloom S, Blumgart L. Characteristics of fibrolamellar hepatocellular carcinoma. A study of nine cases and a review of the literature. Am J Surg 1986; 151: 518-523 [PMID: 2421594 DOI: 10.1016/0002-9610(86)90117-0].
92. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, Piva A, Di Carlo V, Dioguardi N. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-680 [PMID: 1651452 DOI: 10.1056/NEJM199109053251002].
93. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-575 [PMID: 11394657 DOI: 10.1016/S0168-8278(00)00053-2].
94. Gupta S, Bent S, Kohlwes J. Test characteristics of alphafetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139: 46-50 [PMID: 12834318 DOI: 10.7326/0003-4819-139-1-200307010-00012].
95. Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002; 36: 410-417 [PMID: 12143050 DOI: 10.1053/jhep.2002.34744].
96. Fujioka M, Nakashima Y, Nakashima O, Kojiro M. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology 2001; 34: 1128-1134 [PMID: 11732002 DOI: 10.1053/jhep.2001.29202].
97. Bae JS, Park SJ, Park KB, Paik SY, Ryu JK, Choi CK, Hwang TJ. Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma. Korean J Intern Med 2005; 20: 80-85 [PMID: 15906959 DOI: 10.3904/kjim.2005.20.1.80].
98. Johnson PJ, Poon TC, Hjelm NM, Ho CS, Blake C, Ho SK. Structures of disease-specific serum alpha-fetoprotein isoforms. Br J Cancer 2000; 83: 1330-1337 [PMID: 11044358 DOI: 10.1054/bjoc.2000.1441].
99. Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H, Osaki Y, Seki T, Kudo M, Tanaka M. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 2001; 16: 1378-1383 [PMID: 11851836 DOI: 10.1046/j.1440-1746.2001.02643.x].
100. Khien VV, Mao HV, Chinh TT, Ha PT, Bang MH, Lac BV, Hop TV, Tuan NA, Don LV, Taketa K, Satomura S. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers 2001; 16: 105-111 [PMID: 11471892].
101. Mohanty S, Jensen D. Tumor markers and molecular biology. In: Al-Knawy B, Reddy KR, Bolondi L, editors. Hepatocellular carcinoma: a practical approach. New York: Informa Healthcare, 2009: 63-74 [DOI: 10.3109/9780203092880-6].
102. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984; 310: 1427-1431 [PMID: 6201741 DOI: 10.1056/NEJM198405313102204].
103. Nomura F, Ishijima M, Horikoshi A, Nakai T, Ohnishi K. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods. Am J Gastroenterol 1996; 91: 1380-1383 [PMID: 8677999].
104. Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, Suzuki Y, Hata K, Ichii K, Asakura H. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996; 77: 1781-1786 [PMID: 8646674].
105. Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993; 18: 990-997 [PMID: 8406374 DOI: 10.1002/hep.1840180434].
106. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37: 1114-1121 [PMID: 12717392 DOI: 10.1053/jhep.2003.50195].
107. Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, Toshikuni N, Tanaka H, Miyake Y, Matsumoto E, Shiratori Y. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006; 101: 2038-2043 [PMID: 16848811 DOI: 10.1111/j.1572-0241.2006.00681.x].
108. Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012; 56: 1371-1383 [PMID: 22314424 DOI: 10.1016/j.jhep.2011.11.026].
109. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, Wang Z, Qiu S, Wang X, Yang G, Sun H, Tang Z, Wu Y, Zhu H, Fan J. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011; 29: 4781-4788 [PMID: 22105822 DOI: 10.1200/JCO.2011.38.2697].
110. Li L, Guo Z, Wang J, Mao Y, Gao Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci 2012; 57: 2910-2916 [PMID: 22865399 DOI: 10.1007/s10620-012-2317-y].
111. Kew MC, Wolf P, Whittaker D, Rowe P. Tumour-associated isoenzymes of gamma-glutamyl transferase in the serum of patients with hepatocellular carcinoma. Br J Cancer 1984; 50: 451-455 [PMID: 6207851 DOI: 10.1038/bjc.1984.200].
112. Tsai JF, Jeng JE, Chuang LY, Yang ML, Ho MS, Chang WY, Hsieh MY, Lin ZY, Tsai JH. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma. Br J Cancer 1997; 75: 1460-1466 [PMID: 9166938 DOI: 10.1038/bjc.1997.250].
113. Hamazaki K, Gochi A, Shimamura H, Kaihara A, Maruo Y, Doi Y, Orita K, Lygidakis NJ. Serum levels of circulating intercellular adhesion molecule 1 in hepatocellular carcinoma. Hepatogastroenterology 1996; 43: 229-234 [PMID: 8682469].
114. Takahashi H, Saibara T, Iwamura S, Tomita A, Maeda T, Onishi S, Yamamoto Y, Enzan H. Serum alpha-L-fucosidase activity and tumor size in hepatocellular carcinoma. Hepatology 1994; 19: 1414-1417 [PMID: 7514563 DOI: 10.1002/hep.1840190615].
115. International Consensus Group for Hepatocellular Neoplasia; The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664 [PMID: 19177576 DOI: 10.1002/hep.22709].
116. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H, Qin W. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol 2012; 13: 817-826 [PMID: 22738799 DOI: 10.1016/S1470-2045(12)70233-4].
117. Na K, Jeong SK, Lee MJ, Cho SY, Kim SA, Lee MJ, Song SY, Kim H, Kim KS, Lee HW, Paik YK. Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients. Int J Cancer 2013; 133: 408-415 [PMID: 23319432 DOI: 10.1002/ijc.28020].
118. Henry L, Lavabre-Bertrand T, Vercambre L, Ramos J, Carillo S, Guiraud I, Pouderoux P, Bismuth M, Valats JC, Demattei C, Duny Y, Chaze I, Funakoshi N, Bureau JP, Daurès JP, Blanc P. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut 2009; 58: 833-838 [PMID: 19201777 DOI: 10.1136/gut.2008.157016].
119. Hamed M, El-Etreby S, Bahgat M, Attia M, Abdaziz S, Salem D, Kamr W. Is plasma proteasome level a reliable marker of hepatocellular carcinoma in hepatitis c virus related cirrhosis? Hepatology 2012; 56 Suppl 2: S281 [DOI: 10.1016/S0168-8278(12)6 0724-7].
120. Bialecki ES, Ezenekwe AM, Brunt EM, Collins BT, Ponder TB, Bieneman BK, Di Bisceglie AM. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4: 361-368 [PMID: 16527701 DOI: 10.1016/S1542-3565(05)00977-8].
121. Crippin JS. Biopsy of suspicious liver nodules: does it change management? Clin Gastroenterol Hepatol 2006; 4: 296-298 [PMID: 16527691 DOI: 10.1016/j.cgh.2005.12.024].
122. John TG, Garden OJ. Needle track seeding of primary and secondary liver carcinoma after percutaneous liver biopsy. HPB Surg 1993; 6: 199-203; discussion 203-204 [PMID: 8387809 DOI: 10.1155/1993/39539].
123. Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, Terris B, Moutardier V, Farges O, Valla D. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 2001; 35: 254-258 [PMID: 11580148 DOI: 10.1016/S0168-8278(01)00108-8].
124. Huang GT, Sheu JC, Yang PM, Lee HS, Wang TH, Chen DS. Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma-a study based on 420 patients. J Hepatol 1996; 25: 334-338 [PMID: 8895013 DOI: 10.1016/S0168-8278(96)80120-6].
125. Kim SH, Lim HK, Lee WJ, Cho JM, Jang HJ. Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun. Abdom Imaging 2000; 25: 246-250 [PMID: 10823443 DOI: 10.1007/s002610000025].
126. Ohlsson B, Nilsson J, Stenram U, Akerman M, Tranberg KG. Percutaneous fine-needle aspiration cytology in the diagnosis and management of liver tumours. Br J Surg 2002; 89: 757-762 [PMID: 12027987 DOI: 10.1046/j.1365-2168.2002.02111.x].
127. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and metaanalysis. Gut 2008; 57: 1592-1596 [PMID: 18669577 DOI: 10.1136/gut.2008.149062].
128. Ng KK, Poon RT, Lo CM, Liu CL, Lam CM, Ng IO, Fan ST. Impact of preoperative fine-needle aspiration cytologic examination on clinical outcome in patients with hepatocellular carcinoma in a tertiary referral center. Arch Surg 2004; 139: 193-200 [PMID: 14769580 DOI: 10.1001/archsurg.139.2.193].
129. Liu YW, Chen CL, Chen YS, Wang CC, Wang SH, Lin CC. Needle tract implantation of hepatocellular carcinoma after fine needle biopsy. Dig Dis Sci 2007; 52: 228-231 [PMID: 17151805 DOI: 10.1007/s10620-006-9354-3].
130. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 2009; 373: 614-616 [PMID: 19231618 DOI: 10.1016/S0140-6736(09)60381-0].
131. Masuzaki R, Omata M. HCC screening and surveillance. In: Al-Knawy B, Reddy KR, Bolondi L, editors. Hepatocellular carcinoma: a practical approach. London: Informa Healthcare, 2009: 26-35 [DOI: 10.3109/9780203092880-4].
132. Patel SS, Arrington AK, McKenzie S, Mailey B, Ding M, Lee W, Artinyan A, Nissen N, Colquhoun SD, Kim J. Milan Criteria and UCSF Criteria: A Preliminary Comparative Study of Liver Transplantation Outcomes in the United States. Int J Hepatol 2012; 2012: 253517 [PMID: 22957260 DOI: 10.1155/2012/253517].
133. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104].
134. Lencioni R, Crocetti L. Radiofrequency ablation of liver cancer. Tech Vasc Interv Radiol 2007; 10: 38-46 [PMID: 17980317 DOI: 10.1053/j.tvir.2007.08.006].
135. Lencioni R, Crocetti L, De Simone P, Filipponi F. Loco-regional interventional treatment of hepatocellular carcinoma: techniques, outcomes, and future prospects. Transpl Int 2010; 23: 698-703 [PMID: 20492618 DOI: 10.1111/j.1432-2277.2010.01109.x].
136. Lu DS, Yu NC, Raman SS, Limanond P, Lassman C, Murray K, Tong MJ, Amado RG, Busuttil RW. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology 2005; 234: 954-960 [PMID: 15681691 DOI: 10.1148/radiol.2343040153].
137. Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, Sacchetto P, Gandini G, Rizzetto M. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 2008; 43: 727-735 [PMID: 18569991 DOI: 10.1080/00365520701885481].
138. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104: 514-524 [PMID: 19174803 DOI: 10.1038/ajg.2008.80].
139. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-328 [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8].
140. Lencioni R, Crocetti L. Image-guided thermal ablation of hepatocellular carcinoma. Crit Rev Oncol Hematol 2008; 66: 200-207 [PMID: 18304832 DOI: 10.1016/j.critrevonc.2008.01.003].
141. Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, Kondo F, Saisho H. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 2005; 43: 458-464 [PMID: 16005538 DOI: 10.1016/j.jhep.2005.03.033].
142. Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, Konishi J. Small hepatocellular carcinoma: comparison of radiofrequency ablation and percutaneous microwave coagulation therapy. Radiology 2002; 223: 331-337 [PMID: 11997534 DOI: 10.1148/radiol.2232010775].
143. Lencioni R, Pinto F, Armillotta N, Bassi AM, Moretti M, Di Giulio M, Marchi S, Uliana M, Della Capanna S, Lencioni M, Bartolozzi C. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol 1997; 7: 514-519 [PMID: 9204330 DOI: 10.1007/s003300050194].
144. Khan KN, Yatsuhashi H, Yamasaki K, Yamasaki M, Inoue O, Koga M, Yano M. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol 2000; 32: 269-278 [PMID: 10707867 DOI: 10.1016/S0168-8278(00)80072-0].
145. Kuang M, Lu MD, Xie XY, Xu HX, Xu ZF, Liu GJ, Yin XY, Huang JF, Lencioni R. Ethanol ablation of hepatocellular carcinoma Up to 5.0 cm by using a multipronged injection needle with high-dose strategy. Radiology 2009; 253: 552-561 [PMID: 19709992 DOI: 10.1148/radiol.2532082021].
146. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, Hasegawa H, Hirohashi S. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987; 163: 345-351 [PMID: 3031724].
147. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-1763 [PMID: 18471552 DOI: 10.1053/j.gastro.2008.02.090].
148. Guan YS, Ahmad Al-Shatouri M, He Q, Liu WM. Hepatocellular carcinoma: carcinogenesis, establishment, progression, and therapies. Biomed Res Int 2014; 2014: 706142 [PMID: 25028663 DOI: 10.1155/2014/239706].
149. Rammohan A, Sathyanesan J, Ramaswami S, Lakshmanan A, Senthil-Kumar P, Srinivasan UP, Ramasamy R, Ravichandran P. Embolization of liver tumors: Past, present and future. World J Radiol 2012; 4: 405-412 [PMID: 23024842 DOI: 10.4329/wjr. v4.i9.405].
150. Park W, Lim DH, Paik SW, Koh KC, Choi MS, Park CK, Yoo BC, Lee JE, Kang MK, Park YJ, Nam HR, Ahn YC, Huh SJ. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005; 61: 1143-1150 [PMID: 15752895 DOI: 10.1016/j.ijrobp.2004.08.028].
151. Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003; 55: 329-336 [PMID: 12527045 DOI: 10.1016/S0360-3016(02)03929-9].
152. Seo YS, Kim JN, Keum B, Park S, Kwon YD, Kim YS, Jeen YT, Chun HJ, Kim CY, Kim CD, Ryu HS, Um SH. Radiotherapy for 65 patients with advanced unresectable hepatocellular carcinoma. World J Gastroenterol 2008; 14: 2394-2400 [PMID: 18416468 DOI: 10.3748/wjg.14.2394].
153. Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, Tateishi R, Teratani T, Shiina S, Omata M. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer 2006; 106: 1990-1997 [PMID: 16565970 DOI: 10.1002/cncr.21832].
154. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH, Qin LX, Croce CM, Tang ZY, Wang XW. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008; 47: 897-907 [PMID: 18176954 DOI: 10.1002/hep.22160].
155. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, Roberts LR, Schmittgen TD. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14: 419-427 [PMID: 18223217 DOI: 10.1158/1078-0432.CCR-07-0523].
156. Han ZB, Zhong L, Teng MJ, Fan JW, Tang HM, Wu JY, Chen HY, Wang ZW, Qiu GQ, Peng ZH. Identification of recurrencerelated microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol 2012; 6: 445-457 [PMID: 22552153 DOI: 10.1016/j.molonc.2012.04.001].
157. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-1447 [PMID: 19812400 DOI: 10.1056/NEJMoa0901282].
158. Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, Hsu MT, Hsiao M, Huang HD, Tsou AP. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009; 49: 1571-1582 [PMID: 19296470 DOI: 10.1002/hep.22806].
159. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28: 3526-3536 [PMID: 19617899 DOI: 10.1038/onc.2009.211].
160. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69: 5761-5767 [PMID: 19584283 DOI: 10.1158/0008-5472.CAN-08-4797].
161. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009; 41: 843-848 [PMID: 19483683 DOI: 10.1038/ng.392].
162. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L, Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010; 70: 5184-5193 [PMID: 20501828 DOI: 10.1158/0008-5472.CAN-10-0145].
163. Wang C, Song B, Song W, Liu J, Sun A, Wu D, Yu H, Lian J, Chen L, Han J. Underexpressed microRNA-199b-5p targets hypoxiainducible factor-1a in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. J Gastroenterol Hepatol 2011; 26: 1630-1637 [PMID: 21557766 DOI: 10.1111/j.1440-1746.2011.06758.x].
164. Zhang Y, Guo X, Xiong L, Kong X, Xu Y, Liu C, Zou L, Li Z, Zhao J, Lin N. MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett 2012; 586: 4362-4370 [PMID: 23178713 DOI: 10.1016/j.febslet.2012.10.053].
165. Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, Pan Z, Hu X, Zhao Y, Xie H, Jiang G, Chen T, Wang J, Zheng S, Cheng J, Wan D, Yang S, Li Y, Gu J. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 2008; 123: 1616-1622 [PMID: 18649363 DOI: 10.1002/ijc.23693].
166. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-2545 [PMID: 16331254 DOI: 10.1038/sj.onc.1209283].
167. Gu H, Guo X, Zou L, Zhu H, Zhang J. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem 2013; 375: 23-30 [PMID: 23291979].
168. Gramantieri L, Fornari F, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Croce CM, Bolondi L, Negrini M. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 2009; 15: 5073-5081 [PMID: 19671867 DOI: 10.1158/1078-0432.CCR-09-0092].
169. 1 in hepatocellular carcinoma. Mol Biol Rep 2011; 38: 3029-3035 [PMID: 20146005 DOI: 10.1007/s11033-010-9969-5].
170. Rong M, Chen G, Dang Y. Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer 2013; 13: 21 [PMID: 23320393 DOI: 10.1186/1471-2407-13-21].
171. Chen L, Jiang M, Yuan W, Tang H. miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg 2012; 25: 156-161 [PMID: 22583011 DOI: 10.3109/08941939.201 1.618523].
172. Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH. Upregulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 2012; 138: 153-161 [PMID: 22071603 DOI: 10.1007/s00432-011-1076-z].
173. Chen HY, Han ZB, Fan JW, Xia J, Wu JY, Qiu GQ, Tang HM, Peng ZH. miR-203 expression predicts outcome after liver transplantation for hepatocellular carcinoma in cirrhotic liver. Med Oncol 2012; 29: 1859-1865 [PMID: 21786180 DOI: 10.1007/s12032-011-0031-9].
174. Murakami Y, Tamori A, Itami S, Tanahashi T, Toyoda H, Tanaka M, Wu W, Brojigin N, Kaneoka Y, Maeda A, Kumada T, Kawada N, Kubo S, Kuroda M. The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer 2013; 13: 99 [PMID: 23496901 DOI: 10.1186/1471-2407-13-99].
175. Negrini M, Gramantieri L, Sabbioni S, Croce CM. microRNA involvement in hepatocellular carcinoma. Anticancer Agents Med Chem 2011; 11: 500-521 [PMID: 21554203 DOI: 10.2174/187152 011796011037].